Medical Imaging Department, CHU Sainte-Justine, 3175 Côte-Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
Surgery Department, CHU Sainte-Justine, Montreal, QC, Canada.
Pediatr Radiol. 2021 May;51(5):760-772. doi: 10.1007/s00247-020-04930-8. Epub 2021 Feb 9.
The International Society for the Study of Vascular Anomalies (ISSVA) classification distinguishes between common lymphatic malformations and complex lymphatic anomalies. These entities have overlapping features but differing responses to treatment. Surgery has been the mainstream treatment in intra-abdominal lymphatic malformation, with variable reported success in the literature.
The aim of this study was to review the outcome of different treatments for intra-abdominal lymphatic malformations in children.
We retrospectively reviewed all intra-abdominal lymphatic malformations from 1999 to 2019 in children treated by the surgical team or followed in the vascular anomalies clinic of our institution. Children were classified into one of three groups: group A, isolated intra-abdominal lymphatic malformation; group B, common lymphatic malformation in continuity with other regions; or group C, intra-abdominal involvement as part of a complex lymphatic anomaly or associated syndrome.
Fifty intra-abdominal lymphatic malformations were diagnosed; five of these were excluded. In group A (n=28), the treatment was surgical resection (n=26) or sclerosing treatment (n=1), with one case of spontaneous regression; no recurrence was observed in 25 patients. In group B (n=7), three patients had partial resection and all had recurrence; four had sclerotherapy alone with good response. In group C (n=10), therapeutic options included surgery, sclerosing treatment and pharmacotherapy, with variable outcomes.
The management of intra-abdominal malformations requires a team approach. Sclerotherapy is successful in treating macrocystic lymphatic malformation. Surgery is successful in treating isolated intra-abdominal common lymphatic malformation, albeit at times at the cost of intestinal resection, which could be avoided by combining surgery with preoperative sclerotherapy. With surgery there is often limited resectability, and therefore recurrence in intra-abdominal lymphatic malformations that are part of complex lymphatic anomalies associated with syndromes, or in common lymphatic malformations in continuity with other regions. Sclerotherapy is an effective modality in these instances along with pharmacotherapy.
国际脉管性疾病研究学会(ISSVA)分类将常见淋巴管畸形和复杂淋巴管异常区分开来。这些实体具有重叠的特征,但对治疗的反应不同。手术一直是治疗腹腔内淋巴管畸形的主流方法,但文献报道的成功率各不相同。
本研究旨在回顾不同治疗方法对儿童腹腔内淋巴管畸形的治疗效果。
我们回顾性分析了 1999 年至 2019 年在我院血管畸形诊所接受手术治疗或随访的所有儿童腹腔内淋巴管畸形。患儿分为三组:A 组为孤立性腹腔内淋巴管畸形;B 组为与其他部位相连的常见淋巴管畸形;C 组为作为复杂淋巴管异常或相关综合征一部分的腹腔内受累。
诊断出 50 例腹腔内淋巴管畸形,其中 5 例被排除。在 A 组(n=28)中,治疗方法为手术切除(n=26)或硬化治疗(n=1),1 例自发消退;25 例患者无复发。在 B 组(n=7)中,3 例患者行部分切除,均复发;4 例单独行硬化治疗,效果良好。在 C 组(n=10)中,治疗选择包括手术、硬化治疗和药物治疗,结果各不相同。
腹腔内畸形的治疗需要多学科团队协作。硬化治疗对大囊型淋巴管畸形有效。手术治疗孤立性腹腔内常见淋巴管畸形成功率高,但有时需要肠切除,术前硬化治疗联合手术可避免肠切除。手术时往往切除范围有限,因此对于与综合征相关的复杂淋巴管异常或与其他部位相连的常见淋巴管畸形所致的腹腔内淋巴管畸形,会出现复发。在这些情况下,硬化治疗结合药物治疗是一种有效的治疗方法。